We have observed
12 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 publication dated after
December 18, 2012).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Use of KCNQ-Openers for Treating or Reducing the Symptoms of Schizophrenia
DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA
BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME
Heteroaryl amide analogues as P2x7 antagonists
PYRIDINE COMPOUNDS AND USES THEREOF
QUINOLINE DERIVATIVES AS PDE10A ENZYME INHIBITORS
METHODS OF TREATING ALZHEIMER'S DISEASE AND PHARMACEUTICAL COMPOSITIONS THEREOF
RADIOLABELLED PHENYLIMIDAZOLE-BASED LIGANDS
PROCESS FOR THE PURIFICATION OF PHARMACEUTICALLY ACCEPTABLE SALTS OF ESCITALOPRAM
METHOD FOR RESOLUTION OF 4-((1R,3S)-6-CHLORO-3-PHENYL-INDAN-1-YL)-1,2,2-TRIMETHYL-PIPERAZINE AND 1-((1R,3S)-6-CHLORO-3-PHENYL-INDAN, 1-YL)-3,3-DIMETHYL-PIPERAZINE
IMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS